Blueprint Medicines Corp
BPMC127.960USD
-0.250-0.20%
Fechamento 06/13, 16:00（ET）Cotações atrasadas em 15 min
8.26BValor de mercado
PerdaP/L TTM
Mais detalhes de Blueprint Medicines Corp Empresa
Blueprint Medicines Corporation is a fully integrated, commercial-stage, global biopharmaceutical company. The Company invents life-changing medicines in two core, strategic areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and PDGFRA Exon 18 mutant GIST in the United States and Europe. It has a pipeline of research and development programs that range from early science to advanced clinical trials in mast cell-mediated diseases, including systemic mastocytosis (SM) and chronic urticaria, breast cancer, and other solid tumors vulnerable to CDK2 inhibition. Its pipeline includes Elenestinib (BLU-263), BLU-808, and BLU-956. It is developing Elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders. It is advancing BLU-808, a potent and selective wild-type KIT inhibitor, for mast cell diseases.
Informações da empresa
Código da empresaBPMC
Nome da EmpresaBlueprint Medicines Corp
Data de listagemApr 30, 2015
Fundado em2008
CEOMs. Kathryn D (Kate) Haviland
Número de funcionários649
Tipo de títulosOrdinary Share
Fim do ano fiscalApr 30
Endereço45 Sidney Street
CidadeCAMBRIDGE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02139
Telefone16173747580
Sitehttps://www.blueprintmedicines.com/
Código da empresaBPMC
Data de listagemApr 30, 2015
Fundado em2008
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Jeffrey W. (Jeff) Albers, J.D.
Mr. Jeffrey W. (Jeff) Albers, J.D.
Chairman of the Board
Chairman of the Board
142.51K
--
Ms. Kathryn D (Kate) Haviland
Ms. Kathryn D (Kate) Haviland
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
73.23K
+22.22%
Ms. Debra Durso-Bumpus
Ms. Debra Durso-Bumpus
Chief People Officer
Chief People Officer
44.19K
+15.24%
Mr. Michael Landsittel
Mr. Michael Landsittel
Chief Financial Officer
Chief Financial Officer
43.17K
+20.54%
Dr. Philina Lee, Ph.D.
Dr. Philina Lee, Ph.D.
Chief Commercial Officer
Chief Commercial Officer
42.00K
+20.92%
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
President - Research and Development
President - Research and Development
31.96K
+33.54%
Ms. Christina Rossi
Ms. Christina Rossi
Chief Operating Officer
Chief Operating Officer
19.39K
-19.00%
Mr. Percy H. Carter, Ph.D.
Mr. Percy H. Carter, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
16.43K
-13.93%
Ms. Ariel Hurley, CPA
Ms. Ariel Hurley, CPA
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
11.89K
--
Dr. Lynn Seely, M.D.
Dr. Lynn Seely, M.D.
Lead Independent Director
Lead Independent Director
11.01K
+3.36%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Jeffrey W. (Jeff) Albers, J.D.
Mr. Jeffrey W. (Jeff) Albers, J.D.
Chairman of the Board
Chairman of the Board
142.51K
--
Ms. Kathryn D (Kate) Haviland
Ms. Kathryn D (Kate) Haviland
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
73.23K
+22.22%
Ms. Debra Durso-Bumpus
Ms. Debra Durso-Bumpus
Chief People Officer
Chief People Officer
44.19K
+15.24%
Mr. Michael Landsittel
Mr. Michael Landsittel
Chief Financial Officer
Chief Financial Officer
43.17K
+20.54%
Dr. Philina Lee, Ph.D.
Dr. Philina Lee, Ph.D.
Chief Commercial Officer
Chief Commercial Officer
42.00K
+20.92%
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
President - Research and Development
President - Research and Development
31.96K
+33.54%
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de abr
Moeda: USDAtualizado em: dom, 6 de abr
FY2024Q3
FY2024Q2
FY2024Q1
Por EmpresaUSD
Nome
Receita
Proporção
Product revenue
128.18M
100.00%
Collaboration, license and other revenue
1.00K
0.00%
Por RegiãoUSD
Nome
Receita
Proporção
United States
113.13M
88.26%
Rest of the world
15.05M
11.74%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Product revenue
128.18M
100.00%
Collaboration, license and other revenue
1.00K
0.00%
Distribuição de ações
Atualizado em: sex, 16 de mai
Atualizado em: sex, 16 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
10.25%
T. Rowe Price Associates, Inc.
8.28%
BlackRock Institutional Trust Company, N.A.
7.57%
Avoro Capital Advisors LLC
5.95%
Wellington Management Company, LLP
4.75%
Other
63.20%
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
10.25%
T. Rowe Price Associates, Inc.
8.28%
BlackRock Institutional Trust Company, N.A.
7.57%
Avoro Capital Advisors LLC
5.95%
Wellington Management Company, LLP
4.75%
Other
63.20%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
50.24%
Investment Advisor
44.17%
Hedge Fund
8.89%
Research Firm
2.98%
Sovereign Wealth Fund
1.10%
Individual Investor
1.06%
Venture Capital
0.77%
Pension Fund
0.61%
Bank and Trust
0.49%
Participação acionária institucional
Atualizado em: seg, 24 de fev
Atualizado em: seg, 24 de fev
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q1
666
69.26M
107.27%
-1.65M
2024Q4
657
69.17M
108.25%
-2.83M
2024Q3
644
67.12M
105.97%
-7.85M
2024Q2
622
68.23M
108.95%
-6.94M
2024Q1
615
67.81M
110.73%
-5.62M
2023Q4
612
65.87M
108.35%
-10.02M
2023Q3
602
66.47M
109.56%
-7.64M
2023Q2
614
65.78M
108.78%
-8.60M
2023Q1
625
65.63M
109.42%
-10.28M
2022Q4
635
64.56M
107.90%
-8.82M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
6.76M
10.58%
+90.23K
+1.35%
Dec 31, 2024
T. Rowe Price Associates, Inc.
5.62M
8.79%
+315.30K
+5.94%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
5.00M
7.82%
+13.26K
+0.27%
Dec 31, 2024
Avoro Capital Advisors LLC
1.19M
1.85%
+1.19M
--
Dec 31, 2024
Wellington Management Company, LLP
4.28M
6.7%
+316.75K
+7.99%
Dec 31, 2024
State Street Global Advisors (US)
2.50M
3.91%
-265.50K
-9.60%
Dec 31, 2024
Geode Capital Management, L.L.C.
1.49M
2.33%
+9.91K
+0.67%
Dec 31, 2024
William Blair Investment Management, LLC
1.94M
3.04%
+269.90K
+16.12%
Dec 31, 2024
Ver Mais
ETFs Relacionados
Atualizado em: sex, 6 de jun
Atualizado em: sex, 6 de jun
Nome
Proporção
Invesco Biotechnology & Genome ETF
3.22%
Tema Oncology ETF
2.46%
SPDR S&P Biotech ETF
2.26%
Virtus LifeSci Biotech Products ETF
1.91%
Motley Fool Small-Cap Growth ETF
1.68%
Direxion Daily S&P Biotech Bull 3X Shares
1.48%
American Century Focused Dynamic Growth ETF
1.32%
Hypatia Women CEO ETF
0.95%
JPMorgan Fundamental Data Science Small Core ETF
0.93%
Invesco Nasdaq Biotechnology ETF
0.68%
Ver Mais
Invesco Biotechnology & Genome ETF
Proporção3.22%
Tema Oncology ETF
Proporção2.46%
SPDR S&P Biotech ETF
Proporção2.26%
Virtus LifeSci Biotech Products ETF
Proporção1.91%
Motley Fool Small-Cap Growth ETF
Proporção1.68%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção1.48%
American Century Focused Dynamic Growth ETF
Proporção1.32%
Hypatia Women CEO ETF
Proporção0.95%
JPMorgan Fundamental Data Science Small Core ETF
Proporção0.93%
Invesco Nasdaq Biotechnology ETF
Proporção0.68%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
